Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Real-World Use of Emicizumab in Patients with Hemophilia with and without Inhibitors

Isabella McCary, BS, Christine Guelcher, PPCNP-BC, Jan Kuhn, BA, BSN, MSN, Regina Butler, RN-BC, Gita Massey, Michael F. Guerrera, MD, Lance Ballester, MS, Leslie J. Raffini, MD

Blood (2019) 134 (Supplement_1): 1137.

https://doi.org/10.1182/blood-2019-122569

Published: 2019

Journal Articles

Peri-Procedural Management and Outcomes of Patients with Hemophilia on Emicizumab Prophylaxis

Isabella McCary, BS, Christine Guelcher, PPCNP-BC, Jan Kuhn, BA, BSN, MSN, Regina Butler, RN-BC, Michael F. Guerrera, MD, Gita Massey, Leslie J. Raffini, MD

Blood (2019) 134 (Supplement_1): 2396.

https://doi.org/10.1182/blood-2019-126944

Published: 2019

Journal Articles

Dietary Determinants Of The White Blood Cell Count

Pauline D Balkaransingh, MD, David Wheeler, Ph.D., MPH, Yi Ning, MD, MPH, ScD, Marieka A. Helou, MD, Gita Massey, MD

Blood (2013) 122 (21): 1705.

https://doi.org/10.1182/blood.V122.21.1705.1705

Published: 2013

Journal Articles

Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children's Oncology Group Study A2971

Alan S. Gamis, Todd A. Alonzo, Robert B. Gerbing, Joanne M. Hilden, April D. Sorrell, Mukta Sharma, Thomas W. Loew, Robert J. Arceci, Dorothy Barnard, John Doyle, Gita Massey, John Perentesis, Yaddanapudi Ravindranath, Jeffrey Taub, Franklin O. Smith

Blood (2011) 118 (26): 6752–6759.

https://doi.org/10.1182/blood-2011-04-350017

Published: 2011

Includes: Supplemental data

Journal Articles

Factor VIII and Factor IX Mutation Analysis in 600 U.S. Hemophilia Patients: Correlation of Mutation Type with History of Inhibitor

Connie H. Miller, PhD, Craig Hooper, PhD, Thomas C. Abshire, MD, Paula L. Bockenstedt, MD, Doreen B. Brettler, MD, Jorge Di Paola, MD, Gita Massey, MD, Anne T. Neff, MD, Amy D. Shapiro, MD, Michael Tarantino, MD, Brian M. Wicklund, MD, MPH, Marilyn J. Manco-Johnson, MD, Amy L. Dunn, MD, Christine Knoll, MD, Melissa Creary, MPH, Jane Benson, Dorothy Ellingsen, Jennifer Driggers, J. Michael Soucie, PhD

Blood (2008) 112 (11): 1017.

https://doi.org/10.1182/blood.V112.11.1017.1017

Published: 2008

Journal Articles

Experience with a Modified Nijmegen-Bethesda Method for Measurement of Inhibitors in Hemophilia Patients: The CDC Inhibitor Surveillance Pilot Project.

Connie H. Miller, PhD, S. Jean Platt, MT-ASCP, Thomas Abshire, M.D., Doreen Brettler, M.D., Paula Brockenstedt, M.D., Jorge DiPaola, M.D., Gita Massey, M.D., Anne Neff, M.D., Amy Shapiro, M.D., Michael Tarantino, M.D., Brian Wicklund, M.D., Melissa Creary, MA, J. Michael Soucie, Ph.D.

Blood (2007) 110 (11): 1156.

https://doi.org/10.1182/blood.V110.11.1156.1156

Published: 2007

Journal Articles

U.S. Inhibitor Pilot Project: Participant Characteristics and Infusion Log Adherence.

Melissa S. Creary, MPH, John M. Soucie, PhD, Connie H. Miller, PhD, W.C. Hooper, PhD, Thomas C. Abshire, MD, Doreen B. Brettler, MD, Paula L. Pockenstedt, MD, Jorge DiPaola, MD, Gita Massey, MD, Anne T. Neff, MD, Amy D. Shapiro, MD, Michael D. Tarantino, MD, Brian M. Wicklund, MD, Donna DiMichele, MD, Hemophilia Treatment Centers

Blood (2007) 110 (11): 1162.

https://doi.org/10.1182/blood.V110.11.1162.1162

Published: 2007

Journal Articles

Uniform Approach Better Defines Natural History of Transient Myeloproliferative Disorder (TMD) in Down Syndrome (DS) Neonates: Outcomes from Children’ Oncology Group (COG) Study A2971.

Mukta Sharma, MD, Todd A. Alonzo, PhD, April Sorrell, MD, Robert B. Gerbing, MA, Joanne M. Hilden, MD, Robert J. Arceci, MD, PhD, Gita Massey, MD, John J. Doyle, MD, Lisa Bayer, CPNP, John P. Perentesis, MD, Julie Ross, PhD, Franklin O. Smith, MD, Russell Brynes, MD, Jerry Hussong, MD, Lois Hathaway, Alan Gamis, MD

Blood (2006) 108 (11): 376.

https://doi.org/10.1182/blood.V108.11.376.376

Published: 2006

Journal Articles

Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia

Yubin Ge, Alan A. Dombkowski, Katherine M. LaFiura, Dana Tatman, Ravikiran S. Yedidi, Mark L. Stout, Steven A. Buck, Gita Massey, David L. Becton, Howard J. Weinstein, Yaddanapudi Ravindranath, Larry H. Matherly, Jeffrey W. Taub

Blood (2006) 107 (4): 1570–1581.

https://doi.org/10.1182/blood-2005-06-2219

Published: 2006

NARROW

Real-World Use of Emicizumab in Patients with Hemophilia with and without Inhibitors

Peri-Procedural Management and Outcomes of Patients with Hemophilia on Emicizumab Prophylaxis

Dietary Determinants Of The White Blood Cell Count

Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children's Oncology Group Study A2971

Factor VIII and Factor IX Mutation Analysis in 600 U.S. Hemophilia Patients: Correlation of Mutation Type with History of Inhibitor

Experience with a Modified Nijmegen-Bethesda Method for Measurement of Inhibitors in Hemophilia Patients: The CDC Inhibitor Surveillance Pilot Project.

U.S. Inhibitor Pilot Project: Participant Characteristics and Infusion Log Adherence.

Uniform Approach Better Defines Natural History of Transient Myeloproliferative Disorder (TMD) in Down Syndrome (DS) Neonates: Outcomes from Children’ Oncology Group (COG) Study A2971.

Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only